Don’t miss our top Podcasts of 2021! I have compiled a list of our most popular podcasts for 2021 in alphabetical order.

3D cell culture bioreactor system for growing and maintaining spheroids and organoids with the structure and function of in vivo cells

In this podcast, we spoke with Prof. Stephen Fey, Chief Research Officer and Co-founder, CelVivo about the importance of 3D culture and the challenges associated with growing and maintaining culture in 3D.  We also discussed using a 3D culture bioreactor system, which employs clinostat technology to culture spheroids and organoids in a way that maintains the structure and function of in vivo cells.

Addressing the increasing demand for single-use technologies and supply chain shortages with future proof systems

In this podcast, we talked with Phil Sanders, Biotech Chief Innovation Officer, Agilitech, about the increase in demand for single-use equipment and consumables and how this has led to supply chain shortages. We also talk about how to address these issues by incorporating strategies like being brand agnostic and designing systems that are future-proof.

Benefits of using a single-source for discovery, development and GMP manufacture of antibody drug conjugates and other novel bioconjugates

In this podcast, I talked with Dr. Jimmy Li, CEO of WuXi XDC, a WuXi Biologics subsidiary. We discussed the reasons for the formation of WuXi XDC, which was established via a joint venture between WuXi Biologics and WuXi STA, a WuXi AppTec subsidiary, and how this company provides a true single-source for the discovery, development, and GMP manufacture of antibody drug conjugates and other novel bioconjugates with their highly efficient one-stop drug development platform.

CHO Cell Line – From Reliable Workhorse to State-of-the-art Protein Powerhouse

In this podcast, we talked with Alan Dickson, Ph.D., Professor of Biology at the Manchester Institute of Biotechnology, University of Manchester about the evolution of the CHO Cell line from isolation to workhorse of the biomanufacturing industry, to gene edited knockout variants. It is an interesting look at why CHO cells have been so successful and how this success continues to be improved upon for manufacture of emerging therapeutics.

Enabling process development for continuous bioprocessing: Answering the call for small scale tools that are fit for purpose

In this podcast, we discuss the challenges facing biotech companies as they move their therapeutic candidates through the clinic and on to commercial manufacturing. The priority of speed to market is often at odds with issues around development resources, facility space, and infrastructure for both development and manufacturing. Continuous bioprocessing provides solutions for many of these challenges in certain applications, but to deliver on this promise we need fit-for-purpose tools and technologies to enable process development and provide reliable transfer to commercial manufacturing.

Evolving Beyond the Status Quo with Next Generation Buffer Prep Solutions

In this podcast, we spoke with Chris Rombach, Vice President of Sales and Marketing at Asahi Kasei Bioprocess America about buffer prep and delivery systems. We discussed current pain points and how next generation buffer prep solutions can greatly improve upon the status quo, including increasing the use of automation and remote operation, while reducing the overall footprint, labor and cost associated with more traditional approaches.

Implementing Adherent Cell Culture Technology for Cell Therapy Bioprocess

In this podcast, we discuss scale-up and commercial production of cell therapies and new adherent platform technologies such as stacked vessels, microcarriers, and fixed bed bioreactors, that are making it possible for adherent cells to approach similar economies of scale as suspension systems, while meeting the unique biological requirements of cell therapies.

Increasing speed and efficiency of biotherapeutic drug development with stable pools

In this podcast, we talked with Dr. Alison Porter, Head of Expression System Sciences, Lonza, about the use of stable pool expression to reduce drug development timelines. Highlights included implementation of stable pools in current workflows, expected titers, and cutting-edge applications of the technology.

Integrated Freezing Solutions to Minimize Risk and Preserve Product Quality

In this podcast, I talked with Claire Jarmey-Swan, Global Product Manager, Pall Corporation about the evolution of freeze-thaw technologies and how these new methods can streamline the process, minimize loss and maintain the highest product quality.

The Secret Ingredient in Your Gene Therapy Success Recipe

In this podcast, we talk with Ratish Krishnan, Associate Director for Cell & Gene Therapy BioProcessing for the Americas with MilliporeSigma about the tremendous promise gene therapies have for changing the healthcare paradigm, challenges in manufacturing and solutions.

Streamline the ADC Path to the Clinic with One-stop Drug Development and Critical Technology Advancements

In this podcast, I talked with Dr. Jimmy Li, CEO of WuXi XDC, a WuXi Biologics subsidiary. We discussed the reasons for the formation of WuXi XDC, which was established via a joint venture between WuXi Biologics and WuXi STA, a WuXi AppTec subsidiary, and how one-stop drug development organizations greatly streamline a pathway to the clinic. He also shares new technologies available to make the development of Antibody Drug Conjugates (ADCs) more efficient and effective.